^
    Back
    Association details:
    Biomarker:NFE2L2 mutation + CTNNB1 mutation
    Cancer:Hepatocellular Cancer
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Hepatology
    Title:

    Nrf2 and ß-catenin coactivation in hepatocellular cancer: Biological and therapeutic implications

    Published date:
    10/02/2020
    Excerpt:
    NFE2L2-CTNNB1 HCC mice were treated with mTOR inhibitor everolimus (5mg/kg diet ad libitum), which led to >50% decrease in tumor burden...Co-expression of mutant-NFE2L2 and mutant-CTNNB1 led to clinically relevant HCC development in mice, which responded to mTOR inhibitors.
    DOI:
    10.1002/hep.31730